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Abstract  
Purpose of review: Chemotherapy-induced painful neuropathy (CIPN) is a major dose-limiting side-effect of 
several widely used chemotherapeutics. Rodent models of CIPN have been developed using a range of 
dosing regimens to reproduce pain-like behaviours akin to patient-reported symptoms. This review aims to 
connect recent evidence-based suggestions for clinical treatment to preclinical data. 
Recent findings: We will discuss CIPN models evoked by systemic administration of taxanes (paclitaxel and 
docetaxel), platinum-based agents (oxaliplatin and cisplatin), and the proteasome-inhibitor - bortezomib. 
We present an overview of dosing regimens to produce CIPN models and their phenotype of pain-like 
behaviours. In addition, we will discuss how potential, clinically-available treatments affect pain-like 
behaviours in these rodent models, relating those effects to clinical trial data wherever possible. We have 
focussed on anti-depressants, opioids and gabapentinoids given their broad usage. 
Summary: This review outlines the latest description of the most-relevant rodent models of CIPN enabling 
comparison between chemotherapeutics, dosing regimen, rodent strain and gender. Preclinical data 
supports many of the recent suggestions for clinical management of established CIPN and provides 
evidence for potential treatments warranting clinical investigation. Continued research using rodent CIPN 
models will provide much needed understanding of the causal mechanisms of CIPN, leading to new 
treatments for this major clinical problem. 
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Introduction 
Chemotherapy-induced painful neuropathy (CIPN) is a major dose-limiting side effect of several first-line 
chemotherapeutic agents, affecting up to 70% of patients following standard chemotherapy regimens [1-6]. 
Patients describe a range of predominantly sensory, bilateral symptoms in both hands and feet (also 
described as a stocking and glove distribution) including numbness, tingling, ongoing/spontaneous pain, 
hypersensitivity to mechanical and/or cold stimuli. Patients may find their neuropathy significantly impacts 
their daily activities, for example difficulty in buttoning up their shirt due to lack of fine touch sensation and 
/or unable to remove items from a fridge/freezer due to cold hypersensitivity. Pain and sensory 
abnormalities can persist for months or years following the cessation of chemotherapy. Therefore patients 
may well be cancer-free, but suffering a debilitating painful neuropathy as a result of their cancer 
treatment [1, 7, 8]. There is no effective therapy for the prevention of CIPN and only one drug has been 
recommended for the treatment of established CIPN [9]. Currently, the emergence of CIPN results in dose 
reduction or cessation, thus potentially impacting on patient survival, as well as quality of life. CIPN is 
commonly observed following treatment with chemotherapeutics that have different mechanisms of anti-
cancer actions; platinum agents, vinca alkaloids, taxanes, thalidomide, proteasome inhibitors and 
epothilones, reviewed in [10].  The first systemic review and meta-analysis of CIPN prevalence following the 
end of chemotherapy with paclitaxel, bortezomib, cisplatin, oxaliplatin, vincristine and thalidomide (solo or 
combination) treatment was recently reported [11]. CIPN was observed in 68.1%, 60%, and 30% of patients, 
within the first month, at 3 months, and at ≥6 months, respectively, after cessation of chemotherapy [11]. 
In this review, we aim to summarise the studies which have examined rodent models where pain-like 
behaviours were induced by taxanes, platinum agents or bortezomib. Developing animal models of CIPN 
which replicate all the symptoms that patients report is somewhat challenging because numbness, tingling 
and ongoing pain all rely on verbal report from the patient. Thus, most studies have focussed on measuring 
evoked pain behaviours, although investigation into novel measures of ongoing pain in rodents is an 
emerging area. In this review, we also aim to discuss the effects - in these rodent models of CIPN - of agents 
recently suggested as potential treatments for established CIPN in patients [9] namely anti-depressants, 
opioids and gabapentinoids. 
 
Animal models of CIPN 
Taxanes 
Paclitaxel and docetaxel are first-line treatments alone or in combination for solid tumours such as breast, 
ovarian, prostate and non-small cell lung carcinomas. Paclitaxel, a taxane-derived chemotherapeutic, binds 
to -tubulin of microtubules[12], stabilizing microtubules and interfering with spindle-microtubule 
dynamics, arresting mitosis and inducing apoptosis[13]. Docetaxel works via a similar anti-cancer 
mechanism albeit with different potencies [14] and has been associated with higher levels of neurotoxicity 
compared to paclitaxel treatment in metastatic breast cancer patients [15]. Initial work investigating the 
neurotoxicity associated with paclitaxel involved direct application of paclitaxel to peripheral nerves 
resulting in degeneration and specific aggregation of microtubules [16-18]. However, the relevance of such 
local application of chemotherapy to understanding mechanisms of CIPN that are evoked by systemic 
administration is limited due to the high endoneurial concentration. In later studies, rodent models of 
paclitaxel-induced painful neuropathy were developed using systemic paclitaxel administered via 
intravenous or intraperitoneal routes (see Table 1). The majority of regimens for paclitaxel and other 
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chemotherapeutics do not dose animals every day but have a break between each administration in order 
to mimic cycles of chemotherapy. 
Comparison of the integrity of peripheral nerves following different dosing regimens of paclitaxel indicates 
that degeneration is dose-dependent, with greater degrees of degeneration caused by larger cumulative 
doses of paclitaxel [23, 30-33]. Systemic administration of low-doses of paclitaxel did not markedly affect 
neural microtubule structure or cause aggregation as observed following epineural administration [32]. The 
dose-dependent effects of paclitaxel administration have also been observed in patients, where the 
incidence and severity of neuropathic signs and symptoms increased with increasing cumulative doses of 
paclitaxel [34]. Table 1 summarises the evoked pain-like behaviours observed in rodents following different 
administration schedules of paclitaxel. A range of pain-like behaviours are evoked by low-dose (<10mg/kg) 
systemic paclitaxel with both mechanical and cold allodynia observed in rats [19, 20] and mice [27]. At 
higher doses, heat hypoalgesia and motor deficit have been observed, which is likely indicative of 
pronounced neurodegeneration [23, 24, 35, 36]. Recent preclinical studies have typically utilised low-dose 
paclitaxel model consisting of four intraperitoneal injections of 1-2mg/kg paclitaxel on alternate days. Such 
doses do not adversely affect animal health and normal weight gain is observed. Fewer preclinical studies 
have investigated the painful neuropathy associated with docetaxel treatment. However, similar to 
paclitaxel, hypersensitivity to mechanical and thermal stimuli is observed at lower doses [28] and heat 
hypoalgesia is evoked with high cumulative doses of docetaxel [29]. 
 
Platinum Agents 
Cisplatin was the first inorganic anti-tumour agent and the template for future platinum 
chemotherapeutics. Cisplatin is used in the treatment of solid tumours including cervical, testicular, non-
small cell lung, bladder, head and neck cancers. Oxaliplatin is a first-line and adjuvant treatment for 
colorectal cancer, and also used in the treatment of oesophageal and stomach cancer. Both agents react 
with DNA forming inter-/intra-strand platinum-DNA crosslinks, blocking DNA replication/transcription and 
inducing apoptosis [37, 38]. Table 2 describes rodent models of painful neuropathy induced by systemic 
administration of platinum-containing chemotherapeutic agents. Here we will discuss oxaliplatin and 
cisplatin models and observations of induced pain-like behaviours and motor deficits. We did not find any 
reports assessing pain-like behaviours in rodent models of carboplatin-induced painful neuropathy. The 
distinct conditions of acute and chronic pain-like behaviours are modelled in both mice and rats by giving a 
single or repeated doses of platinum-based chemotherapy. Generally, these models are well tolerated with 
only slight impairment of weight gain. However, as the cumulative dose increases more adverse effects are 
observed. A number of groups have used transgenic mice [40, 43, 45, 76], although description of these 
genes is outside the scope of this review. Most studies have used male rodents. However, one study 
compared the effect of gender on development of cisplatin-induced mechanical hypersensitivity finding 
more persistence in male mice [77]. Interestingly, one group has modelled neuropathy evoked by 
combined cisplatin- and paclitaxel- treatment in rats which also had an implanted subcutaneous tumour 
[73, 78]. Typically most models of CIPN involve the solo administration of a given chemotherapeutic in the 
absence of tumour load. 
 
All acute oxaliplatin models show a rapid onset of both cold and mechanical allodynia that persists for more 
than one week following treatment (see Table 2). These symptoms are analogous to the clinical problem 
where patients most frequently report sensitivity to cold/mechanical stimuli soon after drug 
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administration. There are many studies investigating chronic oxaliplatin-induced peripheral neuropathy 
that have used varying doses and regimens of chemotherapy administration (see Table 2). All models 
showed sustained cold and/or mechanical allodynia that lasted for a number of months. Some studies also 
reported mechanical hyperalgesia but, like the acute models, heat hyperalgesia reports are conflicting 
which cannot be attributed to differences in individual/cumulative dose. The majority of cisplatin models of 
CIPN are chronic. However, a single dose of cisplatin evoked mechanical allodynia and heat hyperalgesia, 
but not cold allodynia [39]. With repeated dosing, animals consistently develop mechanical allodynia but 
with mixed outcomes for cold allodynia and heat hyperalgesia (see Table 2). Some studies have 
investigated whether platinum treatment affects motor as well as sensory function. There are reports of 
decreased locomotor activity, yet no change in muscle strength in oxaliplatin models [62, 65, 66]. Cisplatin 
models have shown some reports of decreased locomotor activity and altered gait at high cumulative doses 
of cisplatin [65, 78] whereas no change in other studies [73, 79]. 
 
Bortezomib 
Bortezomib (Velcade®) is a boronic acid dipeptide and the first member of a new class of chemotherapeutic 
agents known as proteasome inhibitors. Bortezomib reversibly binds and inhibits the 26S subunit of the 
proteasome, disrupting critical cell signalling pathways leading to apoptosis [82]. Unlike other 
chemotherapeutics, the effects of proteasome inhibition are more pronounced in malignant cells compared 
to normal cells, with bortezomib sensitising malignant cells to apoptosis, reviewed in [83]. Bortezomib is 
primarily used as a first-line therapy in the treatment of newly diagnosed and relapsed multiple myeloma 
[84], but may also be effective in treatment of solid tumours such as ovarian, renal and prostate 
carcinomas [85, 86]. Table 3 describes rodent models of painful neuropathy induced by systemic 
administration of bortezomib. Mechanical allodynia and hyperalgesia was commonly reported in both rats 
and mice. Cold allodynia was quantified in two rat models [89, 91] but not present in mouse models [87, 
94]. Heat hyperalgesia has been observed in patients treated with bortezomib [96], however assessment in 
rodent models has yet to positively report bortezomib-induced heat hyperalgesia (see Table 3).  
High doses of bortezomib were associated with heat hypoalgesia and motor deficit in mice [95]. However 
motor deficits were not found in several other studies [88, 89], although one mouse model reported 
altered gait following bortezomib [88]. Studies in rats and mice reported that weight gain was impaired by 
bortezomib compared to vehicle-treated animals [92, 94]. Clinically, bortezomib is administered via 
intravenous or subcutaneous routes. However, subcutaneous administration had reduced and/or delayed 
incidence of peripheral neuropathy, without a loss in efficacy or survival rates [97-100] and is preferable to 
patients [101]. More preclinical research on the effect of route of administration on bortezomib-induced 
pain-like behaviours would be interesting. 
 
Effects of clinically available analgesics in rodent models of CIPN 
A recent review of the randomized controlled trials (RCTs) in CIPN patients aimed to produce evidence-
based guidance for CIPN treatments [9]. A moderate recommendation was made for duloxetine. The panel 
suggested that other drugs, e.g. gabapentin, may be offered on the basis of their use in other neuropathic 
pain conditions and in light of the very limited treatment options for CIPN [9]. In this review, we will discuss 
the reported effects of commonly-used analgesics for chronic pain in the rodent models of CIPN. Typically, 
the lack of analgesic drug effects in rodents are not as readily published as observed analgesic effects in 
rodents. Therefore it is not entirely accurate to directly compare a lack of effect observed in clinical trials to 
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preclinical work, given this publication bias. Given space constraints we have focussed on anti-depressants, 
opioids and gabapentinoids and are unable to cite all preclinical studies that show similar effects. 
 
Anti-depressants 
Duloxetine significantly decreased average pain scores, numbness and tingling compared to placebo in CIPN 
patients [102]. Interestingly, patients with CIPN evoked by oxaliplatin responded better to duloxetine 
treatment than paclitaxel-treated CIPN patients [102]. Oral administration of duloxetine inhibited 
chemotherapy-induced mechanical allodynia in paclitaxel-treated mice and bortezomib-treated rats at 30-
100mg/kg doses [89, 103]. Recently, pain investigators have started to develop methods of measuring 
ongoing pain as opposed to evoked hindpaw withdrawal responses to mechanical or cold stimuli. Thermal 
place preference has shown that oxaliplatin-treated animals avoid cold temperatures [71], which can be 
overcome by duloxetine [50].  
A small trial of amitriptyline in CIPN patients found no significant change in pain scores compared to 
placebo [104]. However, there was a trend to improved quality of life measures in amitriptyline-treated 
CIPN patients [104]. Topical treatments containing amitriptyline have been examined in two placebo-
controlled RCTs [105, 106]. Topical application of 4% amitriptyline and 2% ketamine cream twice daily, had 
no effect on pain and numbness scores, in taxane and non-taxane derived CIPN [105]. A trend towards 
improved sensory neuropathy was seen in CIPN patients following topical application of a 
baclofen/amitriptyline/ketamine combination [106]. Given the lack of toxicity and systemic adsorption, 
further trials utilising higher dosing regimens of this combination could be promising. As these topical 
treatments are drug combinations, it is not possible to attribute beneficial effects to a specific drug. Several 
preclinical studies have assessed the effects of amitriptyline in CIPN. In a repeated dosing paradigm, the 
effects of daily intraperitoneal injections of amitriptyline on established paclitaxel-induced mechanical 
hypersensitivity in rats were assessed for four days [107]. Anti-nociceptive effects were only observed 24 
hours after the second dose and then following remaining doses [107]. In oxaliplatin models, 
intraperitoneal amitriptyline had no effect on acute cold allodynia [44]. However, daily oral amitriptyline 
prevented the development of chronic hypersensitivity to cold and mechanical stimuli [68]. Perhaps 
suggesting that analgesic effects of amitriptyline on CIPN are only observed with repeated dosing. Indeed, a 
single oral dose of amitriptyline had no effect on mechanical allodynia induced by bortezomib [89] or 
cisplatin [108].  
A small-scale clinical study showed that venlafaxine was analgesic in chronic CIPN evoked by oxaliplatin 
[109]. In addition, venlafaxine reversed established oxaliplatin-induced cold allodynia in rats [66]. 
Milnacipran is another clinically-available anti-depressant, also used for treatment of fibromyalgia, which 
could be a promising candidate for the treatment of CIPN. In mice, milnacipran prevented acute oxaliplatin-
induced cold allodynia [44], inhibited established oxaliplatin-induced mechanical allodynia [42] and 
inhibited paclitaxel-induced mechanical allodynia with repeated dosing [110]. 
 
Opioids 
We did not find any clinical trials on the use of morphine, oxycodone, fentanyl or tramadol in CIPN patients. 
However, systemic morphine is used as a positive control in preclinical studies assessing potential 
analgesics and efficacy has been demonstrated with the others. Morphine inhibited paclitaxel-induced 
mechanical hypersensitivity, but typically only at high doses (>5mg/kg) [20, 111, 112]. Morphine reversed 
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cisplatin-induced cold allodynia [80] as well as both acute and chronic cold allodynia evoked by oxaliplatin 
[52, 66]. Morphine also inhibited cisplatin- and oxaliplatin-induced mechanical hypersensitivities [58, 108, 
113]. Oxycodone is reported to reverse paclitaxel- and oxaliplatin-induced mechanical allodynia, but mixed 
results are reported with fentanyl administration [58, 59]. Finally, tramadol (10-20mg/kg) administration 
had similar inhibitory effects on pain-like behaviours evoked by paclitaxel [107], oxaliplatin [44] and 
bortezomib [89]. 
 
Gabapentinoids 
Gabapentin administration did not improve pain scores of patients with taxane-/platinum-derived CIPN in a 
RCT against placebo [114]. In preclinical studies, gabapentin is often used as a positive control to assess 
potential analgesics. Gabapentin (100mg/kg) only reduced paclitaxel-induced mechanical hypersensitivity 
in rats with repeated dosing [115]. Interestingly, gabapentin was recently shown to attenuate paclitaxel-
induced gait alterations [116]. Gabapentin prevented acute cold allodynia in mice [44]and reversed chronic 
cold allodynia in rats [66] evoked by oxaliplatin. Effects were also observed in cisplatin-evoked pain-like 
behaviours, with attenuation of cold allodynia [74] and reduction of mechanical allodynia in mice of both 
genders [77] and in rats [108]. In addition, conditioned place preference showed cisplatin-treated animals 
spent more time in an environment associated with gabapentin administration [76]. Two small-scale 
studies have shown pregabalin administration was effective in CIPN caused by oxaliplatin [117, 118]. 
Preclinical studies assessing pregabalin are more limited. However, pregabalin has been shown to inhibit 
several pain-like behaviours evoked by paclitaxel [103], docetaxel [28], oxaliplatin [52] and bortezomib [89].  
 
Conclusion 
Compared to other chronic pain conditions, differential analgesic effects are observed in both CIPN patients 
and rodent models. This suggests different causal mechanisms for CIPN which may or may not be identical 
for all chemotherapeutics that evoke pain. Continued research using the many available rodent models will 
provide much needed mechanistic understanding of the causal mechanisms of CIPN, leading to new 
treatments for this major clinical problem. 
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Table 1: Summary of dose administration and pain-like behaviours in rodent models of taxane-
induced painful neuropathy. Only studies which systemically administered paclitaxel or docetaxel and 
undertook behavioural testing were included. Abbreviations: i.p. intraperitoneal, i.v. intravenous, CA 
= cold allodynia, HH = heat hyperalgesia, HHO = heat hypoalgesia, MA = mechanical allodynia, MH = 
mechanical hyperalgesia, q1d = daily, q2d = alternate days, q1w = once per week. Symbols: (+) 
indicates presence of pain-like behaviour following paclitaxel or docetaxel administration; (-) 
indicates this behaviour was assessed but not evident following paclitaxel or docetaxel 
administration. 
 
Regimen Route Cumulative 
Dose 
Pain-like 
Behaviour 
Species & gender Ref 
PACLITAXEL 
0.5mg/kg, 1mg/kg or 2mg/kg, 
q2d x 4 
i.p. 2mg/kg, 
4mg/kg or 
8mg/kg 
+MA, +MH, 
+HA, +CA 
- motor 
deficit 
Sprague-Dawley rat, 
♂ 
[19, 
20] 
0.1mg/kg, 0.5mg/kg or 
1mg/kg, q1d x 5 days for 2 
weeks 
i.p. 1mg/kg, 
5mg/kg or 
10mg/kg 
+MH, +MA, 
+HA 
Sprague-Dawley rat, 
♂ 
[21] 
16mg/kg or 32 mg/kg x 1 
16mg/kg, q1w x 5 weeks 
i.p. 16mg/kg, 
32mg/kg or 
80 mg/kg 
+MH, +HHO 
 
Sprague-Dawley rat, 
♂ 
[22] 
5mg/kg, q1d x 5 days i.v. 25mg/kg +HHO 
+motor 
deficit 
Wistar rat, ♀ [23] 
21.6mg/kg, q1d x 6 days i.p. 129.6mg/kg +HHO CD1 mice ♂ [24] 
5mg/kg x 1 i.p. 5mg/kg +MA C57BL/6 mice ♂ [25, 
26] 
1mg/kg, q2d x 4 i.p. 4mg/kg +MA 
 
Comparison of all 
‘‘J’’ sub-strains: 
129P3, A, AKR, 
C3H/He, C57BL/6, 
C57BL/10, CBA, 
DBA/2, RIIIS, SM 
mice, ♂ and ♀  
[27] 
1mg/kg, q2d x 4 i.p. 4mg/kg +CA 
-HA 
DBA/2 mice, 
C57BL/6 mice, ♂ 
and ♀ 
[27] 
DOCETAXEL 
10mg/kg x 1 i.v. 10mg/kg +MA, +MH, 
+HH, +CA 
Sprague Dawley rat, 
♂ 
[28] 
10mg/kg, q1w, x 4 weeks i.v. 40mg/kg +HHO 
 
Fischer rat, ♂ [29] 
 
Table 1
Table 2: Summary of dose administration and pain-like behaviours in rodent models of platinum-
induced painful neuropathy. Only studies which systemically administered oxaliplatin or cisplatin and 
undertook behavioural testing were included. Abbreviations: i.p. intraperitoneal, i.v. intravenous, CA 
= cold allodynia, HH = heat hyperalgesia, HHO = heat hypoalgesia, MA = mechanical allodynia, MH = 
mechanical hyperalgesia, q1d = daily, q2d = alternate days, q1w = once per week, q2w = twice per 
week, q3w = thrice per week, q4w = 4 times per week. Symbols: (+) indicates presence of pain-like 
behaviour following oxaliplatin or cisplatin administration; (-) indicates this behaviour was assessed 
but not evident following oxaliplatin or cisplatin administration.  
Regimen Route Cumulative 
dose 
Pain Behaviour Gender/ 
Species 
Refere
nce 
Oxaliplatin acute models 
2 mg/kg x 1 i.v. 2 mg/kg +CA, +HH, +MA ,+MH Sprague-Dawley 
rats ♂ 
[39, 40] 
3 mg/kg x 1 i.p. 3 mg/kg +CA, +MA C57BL/6 mice ♂ [40-42] 
5 mg/kg x 1 i.p. 5 mg/kg +CA, +MA C57BL/6 mice ♂ [43, 44] 
1, 3, or 6 mg/kg x 1 i.p. 1, 3, or 6 mg/kg +CA, +MA C57BL/6 mice ♂ [45, 46] 
10 mg/kg x 1 i.p. 10 mg/kg +CA, +MA ddY mice ♂ [47] 
10 mg/kg x 1 i.p. 10 mg/kg +CA, +HH, +MA CD-1 mice ♂ [48] 
3, 6 or 12 mg/kg x 1 i.p. 3, 6 or 12 mg/kg +CA, +MA  
-HH 
Sprague-Dawley 
rats ♂ 
[49-52] 
Oxaliplatin chronic models 
2 mg/kg q2d x 4 i.p. 8 mg/kg +MA Sprague-Dawley 
rats ♂  
[53] 
1 mg/kg q2w x 4.5 
weeks 
i.v. 9 mg/kg +MA Swiss mice ♂ [54] 
2 mg/kg q1d x 5 i.p. 10 mg/kg +CA, +MA 
- HH 
Sprague-Dawley 
rats ♂ 
[55, 56] 
5 mg/kg q3w x 1 week i.p. 15 mg/kg +MA Sprague-Dawley 
rats ♂ 
[57] 
2 mg/kg q2w x 4 
weeks 
i.p. 16 mg/kg +MA Sprague-Dawley 
rats ♂ 
[58, 59] 
0.6, 2 or 6mg/kg q1w x 
3 weeks 
i.p. 1.8, 6 or 18 
mg/kg 
+MH Wistar rats ♂ [60] 
3 mg/kg day 1, 3, 5, 8, 
11 and 15 
i.p. 18 mg/kg +MH Wistar rats ♂ [61]  
2 mg/kg q2w x 4.5 
weeks 
i.p. 18 mg/kg +CA, +MA, +MH 
- Motor deficit 
Wistar rats ♂ [62] 
A. 0.5, 1, 2, or 5 mg/kg  
x 1 
B. 5 mg/kg q1w x 4 
weeks 
i.v. A. 0.5, 1, 2, or 5 
mg/kg   
B. 20 mg/kg 
+CA, +HH, +MA, Sprague-Dawley 
rats ♂ 
[63] 
3.5 mg/kg q2w x 4 
weeks 
i.v. 28 mg/kg +CA, +MA 
-  HH 
BALB/c mice ♀ [64] 
3mg/kg q1d x 5 for 2 
cycles, with 5 day 
break  
i.p. 30 mg/kg +CA, +MA, +motor deficit 
- HH - grip strength deficit 
C57BL6J mice ♂ [65] 
1, 2 or 4 mg/kg, q2w x 
4.5 weeks 
i.v. 9, 18 or 32 
mg/kg 
+CA, +HH, +MA, +MH, +grip 
strength deficit 
- motor deficit  
Sprague-Dawley 
rats ♂ 
[66] 
Table 2
4 mg/kg q2w x 4 
weeks  
i.p. 32 mg/kg +CA, +MA Sprague-Dawley 
rats ♂ 
[59, 67-
70] 
2 or 4 mg/kg q2w x 4 
weeks 
i.p. 16 or 32 mg/kg +MA Sprague-Dawley 
rats ♂ 
[67] 
A. 15 mg/kg x 1 
B. 15 mg/kg q1w x 3 
weeks  
i.p. A. 15 mg/kg 
B. 45 mg/kg 
+CA, +MA BALB/c mice ♂ [71] 
Cisplatin models      
2 mg/kg x 1 i.v. 2 mg/kg +HH, +MA 
- CA 
Sprague-Dawley 
rats ♂ 
[39] 
0.1, 0.5, or 1 mg/kg 
q2d x 3 
i.p. 0.3, 1.5 or 3 
mg/kg 
+HH, +MA Sprague-Dawley 
rats ♂ 
[72] 
3 mg/kg q1w x 2 
weeks 
i.p. 6 mg/kg +HHO  
- motor deficit 
Dark agouti rats 
♀ 
[73] 
3 mg/kg q1w x 3 
weeks 
i.p. 9 mg/kg +CA, +MA 
- HH 
Sprague-Dawley 
rats ♂ 
[74] 
1 or 2 mg/kg q1w x 5 
weeks 
i.p. 5 or 10 mg/kg +MA Wistar rats ♂ [75] 
2.3 mg/kg q2d x 6  i.p. 13.8 mg/kg +MA 
 
C57BL/6 mice ♂ 
+♀ 
[76, 77] 
2 mg/kg q2w x 4 
weeks 
i.p. 16 mg/kg +HHO, +motor deficit Dark agouti rats 
♀ 
[78] 
2 mg/kg q2w x 4.5 
weeks 
i.p. 18 mg/kg +HH 
- Motor deficit 
Wistar rats ♀ [79] 
5 mg/kg q1w x 4 
weeks 
i.p. 20 mg/kg +CA, +MA C57BL6J mice, 
gender not 
specified 
[80] 
A. 3 mg/kg q1w x 5 
weeks 
B. 2 mg/kg q2w x 5 
weeks 
C. 1 mg/kg q3w x 5 
weeks 
i.p. A. 15 mg/kg  
B. 20 mg/kg 
C. 15 mg/kg 
 
+CA, +MA 
- motor deficit 
Sprague-Dawley 
rats ♂ 
[81] 
2.3 mg/kg q1d x 5 for 
2 cycles, with 5 day 
break 
i.p. 23 mg/kg +MA, +HH, +motor deficit 
- CA - grip strength deficit 
C57BL6J mice ♂ [65] 
 
1 
 
Table 3. Summary of dose administration and pain-like behaviours in rodent models of bortezomib-induced 
painful neuropathy. Only studies which systemically administered bortezomib and undertook behavioural 
testing were included. Abbreviations: i.p., intraperitoneal, i.v., intravenous, s.c., subcutaneous, CA = cold 
allodynia, HH = heat hyperalgesia, HHO = heat hypoalgesia, MA = mechanical allodynia, MH = mechanical 
hyperalgesia, q1d = daily, q2w = twice per week, q3w = thrice per week, q4w = 4 times per week. Symbols: 
(+) indicates presence of pain-like behaviour following bortezomib administration; (-) indicates this 
behaviour was assessed but not evident following bortezomib administration. 
Regimen Route Cumulative 
Dose 
Pain Behaviour Species & gender Reference 
0.03-0.3 mg/kg x 1  i.v. 0.03-0.3 
mg/kg 
+MA, +MH 
-CA, -HH 
C57BL/6NCr 
mouse, ♂ 
[87] 
0.4mg/kg, q3w x4 
weeks 
i.p. 4.8 mg/kg +MA, +gait alteration, 
+reduced open field 
movement 
- Motor deficit 
C57Bl/6J mouse, 
♂ 
[88] 
0.05, 0.1 or 0.2 
mg/kg, q2w x2 
weeks 
i.p. 0.2, 0.4 or 
0.8 mg/kg 
+MA, +CA 
-HH, -motor deficit 
Sprague Dawley 
rat, ♂ 
[89] 
0.15 mg/kg, q4w i.p. 0.6 mg/kg +MH 
-HH, -CA, -motor deficit 
Sprague Dawley 
rat, ♂ 
[90] 
0.2mg/kg, q1d x5 
days 
i.p. 1 mg/kg +MA, +MH, +CA 
-HH 
Sprague Dawley 
rat, ♂ 
[91] 
0.15 mg/kg or 0.2 
mg/kg, q3w, x8 
weeks 
i.v. 3.6 or 4.8 
mg/kg 
+MA 
-HH 
Wistar rat, ♀ [92] 
0.2 mg/kg, q3w, x8 
weeks 
i.v. 4.8 mg/kg +MH 
-HH 
Wistar rat, ♀ [93] 
0.8 mg/kg, q2w, x4 
weeks 
i.v. 6.4 mg/kg 
 
+MH 
-HH, -CA 
Balb/c mouse, ♀ [94] 
1.0 mg/kg, q2w, x6 
weeks 
s.c. 12 mg/kg +HH, +motor deficit Swiss OF1 
mouse,♀ 
[95] 
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